Endocrine Abstracts

Objectives: In May 2016, the local thyroid cancer tumor group proposed and adopted specific thyroid lobectomy recommendations based on the 2015 ATA guidelines. ThyroSPEC molecular testing was introduced for all Bethesda III and IV lesions in August 2020. The goal of this study was to evaluate the implementation of the ATA lobectomy guidelines and the introduction of ThyroSPEC molecular testing on rates of upfront total thyroidectomy (TTx), diagnostic lobectomy for Bethesda I-I...

Objectives: Molecular diagnostic tests for indeterminate thyroid nodules (ITNs) are marketed based on negative predictive value (NPV) and benign call rate. Arguments that unnecessary surgeries are avoided based on NPV/BCR incorrectly assume that all ITNs would undergo diagnostic surgery in the absence of molecular testing. In our practice with centralized triage and cytopathology the resection and malignancy rate, respectively, were 21% and 26% for AUS/FLUS and 56% and 43% for...